Triplatin tetranitrat

Triplatin tetranitrat
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	56841764
Hemijski podaci
Formula	C12H54Cl2N14O12Pt3
Mol. masa	1242,8018 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/2C6H14N2.CH3.2ClH.4HNO3.5H2N.3Pt/c27-5-3-1-2-4-6-8;;;;42-1(3)4;;;;;;;;/h27-8H,1-6H2;1H3;21H;4(H,2,3,4);51H2;;;/q2-2;-1;;;;;;;5-1;2*+1;+4/p-2; Key: JNZIJTVZGOHQBD-UHFFFAOYSA-L
Sinonimi	BBR3464, BBR 3464, BBR-3464, C114062, ((trans-PtCl(NH3)2)2(trans-Pt(NH3)2(NH2(CH2)6NH2)2))(NO3)4
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Triplatin tetranitrat (rINN; BBR3464) je citotoksični lek baziran na platini koji je prošao kroz Klinička ispitivanja za tretmn ljudskog kancera.^[3] Leko formira adukte sa ćelijskom DNK, čime se sprečava DNK transkripcija i replikacija, te se indukuje apoptoza. Drugi lekovi protiv kancera koji sadrže platinu su cisplatin, karboplatin, i oksaliplatin.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). „The status of platinum anticancer drugs in the clinic and in clinical trials”. Dalton Transactions 39 (35): 8113–27. DOI:10.1039/C0DT00292E. PMID 20593091.